Hana Safah, MD, details the prevention and management of cytokine release syndrome (CRS) and immune effector cell-associated neurotoxicity syndrome (ICANS) in patients receiving BCMA-directed bispecific antibodies for relapsed/refractory multiple myeloma.
Supportive Care Helps Manage AEs With Teclistamab in R/R Multiple Myeloma
December 13th 2024During a Case-Based Roundtable® event, Hana Safah, MD, discussed updated data and adverse event management related to teclistamab in patients with multiple myeloma in the second article of a 2-part series.
Read More